|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
There were significant immunophenotypic differences between adenosquamous carcinomas and pure invasive stratified mucin-producing carcinomas with regard to HPV (p < 0.0001), PAX8 (p = 0.038; more in adenosquamous carcinoma), p40 (p < 0.0001; more in adenosquamous carcinoma), p63 (p = 0.0018; more in adenosquamous carcinoma) and MUC6 (p < 0.0001; less in adenosquamous carcinoma), HNF-1beta (p = 0.0023), vimentin (p = 0.0003), p53 (p = 0.0004), and CK7 (p = 0.0002) expression.
|
30258209 |
2019 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carcinomas of the thyroid with Ewing family tumor element (CEFTEs) are small-cell thyroid tumors with epithelial differentiation that disclose p63 expression and EWSR1-FLI1 rearrangement, carry a favorable prognosis and may co-exist with papillary thyroid carcinoma (PTC) foci.
|
28236059 |
2017 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast to conventional urothelial carcinomas that based on their expression can be equally divided into luminal and basal subtypes, micropapillary cancer is almost exclusively luminal, displaying enrichment of active peroxisome proliferator-activated receptor γ and suppression of p63 target genes.
|
26988609 |
2016 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The numbers of monotonous clusters with p63 differed significantly between benign lesions, ductal carcinoma in situ (DCIS)/lobular carcinoma in situ (LCIS) and invasive carcinomas (P < 0.001).
|
27060708 |
2016 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The percentage of positive TKTL1 and p63 expression in gastric carcinomas was significantly higher than that in normal gastric mucosa tissues (P < 0.05).
|
26406948 |
2015 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CK5-positive carcinomas expressed p40 more frequently than p63 (18/19 vs. 8/19) and the staining was more marked.
|
26330357 |
2015 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of p63 is the sole independent marker of aggressiveness in localised (stage I-II) Merkel cell carcinomas.
|
21765392 |
2011 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Thus, our data indicate that mechanisms other than autophagy contribute to the tumorigenicity of microsatellite unstable colon carcinomas with monoallelic UVRAG mutation.
|
20724836 |
2010 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Presence of p63 in invasive breast carcinomas of luminal type, as seen at molecular level, suggests caution to include p63 as a marker of basal-like carcinomas.
|
20225093 |
2010 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
For this, we analyzed human UVRAG exon 8 in 45 gastric carcinomas with MSI and 92 gastric carcinomas without MSI by a single-strand conformation polymorphism analysis.
|
18495205 |
2008 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We examined expressions of the p63 and p73 genes and proteins in normal biliary epithelia, biliary dysplasias, and EBD carcinomas using immunohistochemistry and RT-PCR analysis. p63 and p73 proteins were overexpressed in 26.3 and 41.0% of EBD carcinomas, respectively. p63 protein expression was more frequent in tumors with vascular invasion (P = 0.002) and distal location (P = 0.04), while p73 expression was more common in cancers with deeper tumor invasion (P = 0.04).
|
17385050 |
2007 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Importantly, when S100P and p63 were combined 95% of urothelial carcinomas were labeled by one or both markers.
|
17460449 |
2007 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We evaluated the p63 immunoexpression in 91 ovarian benign cystadenomas (29 mucinous and 62 serous) and in 29 ovarian malignant tumors (3 mucinous borderline, 3 serous borderline, 17 serous carcinomas, 2 endometrioid, 2 undifferentiated, 1 mucinous, and 1 clear-cell carcinoma) using a monoclonal antibody clone 4A4 (1:200), which recognizes all p63 variants.
|
16445626 |
2006 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunoreactivity for p63 and p73 was evident in epithelial cells neighboring the basement membrane in developing and neoplastic odontogenic tissues. p63 expression in desmoplastic ameloblastomas was significantly higher than in acanthomatous and granular cell ameloblastomas, and ameloblastic carcinomas showed higher p63 expression than metastasizing ameloblastomas. p73 expression was significantly higher in plexiform ameloblastomas than in follicular ameloblastomas, and basal cell ameloblastomas showed higher p73 expression than granular cell ameloblastomas. mRNA transcripts for Delta Np63 and TAp73 were detected in all developing and neoplastic odontogenic tissues.
|
15752257 |
2005 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We propose the inclusion of p63 as part of the diagnostic workup of challenging spindle cell tumors of the breast as a highly specific marker for metaplastic carcinomas.
|
15489655 |
2004 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of p63 (TA and deltaN isoforms) in human primary well differentiated buccal carcinomas.
|
15183414 |
2004 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We recently reported that impaired p63 expression is a common feature of high-grade invasive urothelial carcinomas and associates with reduced beta-catenin.
|
14654529 |
2003 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Positive immunostaining for p63 was found in 55/68 (81%) carcinomas of 29 patients.
|
11948487 |
2002 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It has recently been confirmed that p63 is expressed in the basal cells of normal prostate glands but not in prostatic carcinomas.
|
12185332 |
2002 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on our findings, the balance of probabilities favors that p63 might play a role in the pattern of differentiation and in the oncogenesis of usual carcinomas of the skin.
|
12358808 |
2002 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
On the basis of its consistency and magnitude of cancer cell-specific expression, we propose AMACR as an important new marker of prostate cancer and that its use in combination with p63 staining will form the basis for an improved staining method for the identification of prostate carcinomas.
|
11956072 |
2002 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A strong association between HPV 16 and p63 positivity was identified because of the colocalization of both within tumors of squamous phenotype. p63 is a powerful marker for squamous differentiation and, when diffusely expressed, excludes a glandular or neuroendocrine differentiation. p63 may be useful for differentiating pure squamous or glandular from adenosquamous carcinomas, tracking shifts in differentiation within tumors, supporting (by its absence) the diagnosis of neuroendocrine carcinomas, and clarifying the spectrum of poorly differentiated carcinomas lacking either squamous or neuroendocrine differentiation.
|
11381365 |
2001 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate the relative contribution of PIK3CA and p63 in the pathogenesis of head and neck carcinomas displaying a 3q gain, we measured their respective transcription levels in tumors with previously determined gene copy number.
|
11358835 |
2001 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Neither p53, p73 nor p63 were related to prognosis. p73 and p63 have rarely been found to be mutated in gastric carcinomas, but both proteins were expressed in only a subset of tumours.
|
11592094 |
2001 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Over-expression of p63 alpha, and in particular the delta N form, was frequently seen in carcinomas.
|
10897041 |
2000 |